Merck and Orion collaborate for the development and commercialization of ODM-208
Orion to receive an upfront payment of USD 290 million
Orion to receive an upfront payment of USD 290 million
Upgrades and global expansion provide additional control, visibility, reliability and recovery for patient-critical, time-and temperature-sensitive products
Syngene's collaboration with Zoetis started in 2011
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
The expansion at CDMO facility in South Haven, will bring a new 4,000-gallon multi-use reactor train consisting of glass lined and stainless-steel materials of construction
Athos will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples
MINYM can be safely used by patients above 9 years of age.
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
Subscribe To Our Newsletter & Stay Updated